Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni
1453  

Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni

Gilead Sciences, Inc. announced plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will ...

September 25, 2018
News  
FDA Grants Fast Track Designation to Hepatitis B Drug
1270  

FDA Grants Fast Track Designation to Hepatitis B Drug

The FDA recently granted Fast Track designation to Assembly Biosciences, Inc’s novel treatment for patients with chronic hepatitis B virus (HBV) infection. The drug, ABI-H0731, is the manufacturer’s lead oral HBV core inhibitor, according to a press release.

August 07, 2018
News  
Hepatitis C virus treatment as prevention in people who inject drugs
1167  

Hepatitis C virus treatment as prevention in people who inject drugs

Alexei Zelenev and colleagues presented an elegant analysis of treatment-as-prevention (TasP) for hepatitis C virus (HCV) infection in people who inject drugs (PWID), using a model capturing the dynamics of the injecting-partnership network, which is superior to the more common approaches of compartmental modelling (omitting ...

March 23, 2018
News  
Ukraine is hosting the “European HIV-Hepatitis Testing Week”
1367  

Ukraine is hosting the “European HIV-Hepatitis Testing Week”

16 non-governmental organizations from different regions of the country will participate in the European initiative aimed at encouraging people to get tested for HIV and hepatitis, including the members of the “Consortium of Key Communities” representing Ukraine in the ECUO PLWH. The European HIV-Hepatitis Testing Week will ...

November 06, 2017
ECUO  News  
Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection
1974  

Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

AbbVie’s new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris. Glecaprevir/pibrentasvir (Maviret) is expected to be approved ...

July 26, 2017
EATG  News